T-cell receptor beta variable 9 (TRBV9) (TRBV9)

T-cell receptor beta variable 9 (TRBV9) is a specific protein segment of the beta chain of the T-cell receptor (TCR) complex, which is essential for antigen recognition by T lymphocytes (UniProt, 2024). In patients with Ankylosing Spondylitis (AS) and other axial spondyloarthritides, research has identified a pathological expansion of T-cell clones expressing the TRBV9 segment, particularly in those who are HLA-B27 positive (Britanova et al., 2020, Nature Communications). These specific T cells are believed to drive the autoimmune inflammatory process by reacting against self-antigens in the joints and spine (Nasonov et al., 2023, Rheumatology Science and Practice). Therapeutic strategies targeting TRBV9, such as the monoclonal antibody seniprutug (BCD-180), aim to selectively deplete these pathogenic T-cell populations through antibody-dependent cellular cytotoxicity (ADCC) (Biocad, 2024). This targeted approach represents a significant advancement in precision medicine for autoimmune diseases, as it eliminates the specific drivers of inflammation while sparing the majority of the functional immune system. Clinical trials have shown that depleting TRBV9+ T cells can lead to significant clinical improvement and reduction in inflammatory markers in AS patients (ClinicalTrials.gov, NCT05438446).

Other names

TCRBV9TRBV9-1T-cell receptor beta chain variable region 9

Targeted depletion of TRBV9-positive T-cell clones via antibody-dependent cellular cytotoxicity (ADCC) (Britanova et al., 2020).